Immunotherapy Drug Improves Survival, Lasting Responses for Extensive-Stage SCLC
November 17th 2019Imfinzi (durvalumab) is the first immunotherapy to show improved survival and lasting responses for patients with extensive-stage small cell lung cancer (SCLC), according to findings from the phase 3 CASPIAN trial.
Friday Frontline: Cancer Updates, Research and Education on October 25, 2019
October 25th 2019From the Food and Drug Administration’s call to action over breast implant-associated illness and lymphoma to a four-time survivor’s college football debut, here’s what is making headlines in the cancer space this week.